Skip to main content
. 2012 Feb 27;10(3):551–558. doi: 10.3390/md10030551

Table 2.

Cytotoxicity of kiamycin (1) and adriamycin against human cell lines HL-60 (leukemia), BEL-7402 (hepatoma), and A549 (lung adenocarcinoma) at 10−4 M.

Cancer Cell Line Inhibition Rate by 1 (%) Inhibition Rate by Adriamycin (%)
human leukemic cell line HL-60 68.8 70.0
human hepatoma cell line BEL-7402 31.7 79.3
human lung adenocarcinoma cell line A549 55.9 80.8